ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2131 entries already.
VarmX will use the combination of a €7.5m Series A financing co-led by BioGeneration Ventures (BGV) and Dutch regional development company InnovationQuarter plus an €5m innovation credit from the Netherlands Enterprise Agency (RVO.nl) to develop a modified blood coagulation factor X to prevent severe bleeding in haemophilia patients.
The EMA’s CHMP recommended nine medicines including six orphan medicines for EU market approval on Friday.
German and US researchers have designed a mouse model that exactly mimics the mechanisms of hepatitis infection in men.
Agribiotech lobby group ISAAA reports that global GMO acreage has grown to 189.8 million hectares in 2017 -3% or 4.7 million hectares more than in 2016.
Roche’s Japanese arm Chugai today returned all rights from a 2016 licence agreement on the RNA polymerase II blocker lurbinectedin to Spanish oncology specialist PharmaMar SA.
How do novel technologies affect the world’s largest enzyme producer? At the GBS, European Biotechnology asked Thomas Videbaeck, PhD, COO and Executive VP Research, Innovation and Supply.
Selvita spin-out NodThera Ltd raised £28 million (€31.8m) in a Series A financing round led by Sofinnova Partners and 5AM Ventures and co-financed by Epidarex Capital and F-Prime Capital Partners.
Special immune cells that protect the lining of the gut remain in a semi-active state, ready to fend off a pathogen at any moment, thanks to the composition of their mitochondrial membrane, a new study reveals.
A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.
Swiss Novimmune SA has exclusively sold a licence option on its lead product NI-1701 (now renamed TG-1801), a bispecific anti-CD47/anti-CD19 antibody designed to trea B-cell blood cancers, to TG Therapeutics Inc.